Investigating a new way to reduce lung injury caused by sepsis
Official title: GPR68 as a novel modulator of septic lung injury
Funded at University of Maryland Baltimore · NIH-10896203 · Data updated 2026-11-12
This study is looking at how a specific receptor in the body affects lung inflammation and injury in people with severe infections like sepsis, especially those who develop breathing problems known as ARDS, to find new ways to help treat these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $604,629 |
| NIH project number | 5R01HL167192-02 |
| Project ID | NIH-10896203 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with severe sepsis, particularly those who are at risk of developing ARDS.
✕Less likely to help
Patients with mild infections or those who do not develop sepsis or ARDS may not benefit from this research.
What this research studies
This research focuses on understanding how a specific receptor, GPR68, influences lung inflammation and injury in patients suffering from sepsis, particularly those who develop Acute Respiratory Distress Syndrome (ARDS). The study will explore the mechanisms by which GPR68 modulates the body's inflammatory response to infections, aiming to identify potential therapeutic targets. By utilizing advanced laboratory techniques and animal models, researchers hope to uncover new insights that could lead to effective treatments for ARDS. Patients with severe sepsis and ARDS may benefit from the findings of this research, which seeks to improve current management strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce lung injury and improve survival rates for patients with sepsis and ARDS.
How similar studies have gone: While the specific approach of targeting GPR68 is novel, similar research has shown promise in understanding inflammatory responses in sepsis and ARDS.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Birukova, Anna — University of Maryland Baltimore
- Study coordinator: Birukova, Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.